Staffan is one of the founders of AroCell and has been active as an independent researcher since 1981. He has made a decisive contribution to the development of the company since it was founded in 2003. Staffan has devoted a large part of his research to studies of Thymidine kinase and its use as a biomarker in cancer and has published 29 publications and holds four approved patent families in many countries and two ongoing patent applications in the field.

“AroCell has developed very positively in recent years and as the company is now entering a commercial phase, it is the right time for me to leave the operational work. However, I look forward with great pleasure to following and supporting the company through my work in AroCell's Advisory Board", says Staffan Eriksson.

“It has been a privilege and a pleasure to have had the opportunity to work with Staffan and take part in his deep knowledge of TK1 and its use as a biomarker. However, Staffan does not leave the company but remains on our Advisory Board where he will continue to contribute with his experience and extensive knowledge", says Anders Hultman, CEO of AroCell.

Former CFO Anders Hultman has been appointed new CEO. During the more than two years he has been at AroCell, Anders has done an exceptional job together with the former CEO Michael Brobjer, which enables a simple and smooth transition to the new role. Anders is very well acquainted with the company's strategies and plans to take the AroCell TK 210 ELISA to the next level. In addition to a solid experience as CFO, Anders has the business acumen needed for a demanding CEO assignment. He has previous experience of successfully running both listed and unlisted companies in various industries.

"I am honored to take over as CEO after Michael Brobjer. AroCell has a fantastic product and is in an important and interesting phase where full focus is on the strengthened commercialization of AroCell TK 210 ELISA. I look forward to leading AroCell to the next phase together with our professional team ", says CEO Anders Hultman.

Former CEO Michael Brobjer has resigned at his request. He and his family are going on a longer sailing voyage. Michael resigns today as CEO and thus enables a smooth transition for the new CEO Anders Hultman. During the remaining time at the company, Michael will focus on the launch of AroCell TK 210 ELISA in the US prior to the FDA approval of AroCell's 510(k) submission. Michael will work his last day at AroCell on April 30th  but will continue as a consultant for AroCell.

"I look forward with great excitement to AroCell's continued journey and am convinced of its success. At the same time, I am on my way to the adventure of my life, something that we in the family promised each other many years ago. It will be very exciting to follow AroCell's continued development from the oceans ", says former CEO Michael Brobjer.

“Michael Brobjer has made a great contribution to AroCell and through his leadership taken the company to a new level. I am pleased that through the appointment of Anders Hultman, we can confidently ensure that AroCell continues to pursue its successful work to offer a better tool to support oncologists in the treatment of cancer while placing further focus on our US launch," said Claes Post, Chairman of the Board at AroCell.